Dr. Jorge Castillo – Associate Professor of Medicine, Harvard University – presenting “Treatment around the corner for Waldenstroms Macroglobulinemia” at the 2019 WMFC Educational Forum Toronto – April 2019
Dr. Christine Chen from the Princess Margaret Cancer Centre presenting on ” Navigating Treatment Options for Waldenstrom’s Macroglobulinemia in Canada” at the 2019 WMFC Educational Forum Toronto – April 2019
Dr. Ruben Carrasco from the Department of Pathology, BWH and Department of Oncologic Pathology, DFCI presenting: Engineering a mouse model of Lymphoplasmacytic Lymphoma/Waldenstroms Macroglobulinemia (LPL/WM) at the 2019 WMFC Educational Forum Toronto – April 2019
Experts remark on goals of therapy and considerations for first-line therapy in patients with Waldenström macroglobulinemia.
The 5th International IWMF Doctor – Patient Summit was held in New York City from October 13-14.
The IWMF has generously provided videos of the sessions on their website.
To access the sessions, please CLICK HERE.
Patients with symptomatic Waldenström macroglobulinemia (WM) benefit from first-line treatment with ibrutinib, which Steven P. Treon, MD, PhD, Bing Center for Waldenström Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, and colleagues describe as being highly active and safe… Continue reading
A head-to-head, open-label, multicenter, phase 3 clinical trial comparing the efficacy and safety of zanubrutinib (BGB-3111) with ibrutinib in patients with Waldenström macroglobulinemia (WM) is underway (ClinicalTrials.org Identifier: NCT03053440).1 The study also seeks to evaluate the… Continue reading
This morning, August 27, 2018, the US Food and Drug Administration (FDA) approved ibrutinib (IMBRUVICA, AbbVie) in combination with rituximab (RITUXAN) for the treatment of Waldenström’s macroglobulinemia. This combination is the first and only chemotherapy-free treatment option for patients with… Continue reading
Zanubrutinib (BGB-3111), an investigational small molecule inhibitor of BTK, showed promising activity in patients with Waldenström macroglobulinemia (WM), according to updated results presented at the 2018 European Hematology Association Congress.
First author Judith Trotman, MBChB, FRACP, FRCPA, clinical professor of… Continue reading